Publication: Facilitating tailored therapeutic strategies for glioblastoma through an orthotopic patient-derived xenograft platform
Authors
Lee, Hye Won ; Lee, Kyoungmin ; Kim, Dong Geon ; Yang, Hee Kyoung ; Nam, Do-Hyun
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia. Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
10.14670/HH-11-695
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Despite years of research into its
pathobiology and continuing clinical trials for novel
therapies, the prognosis for patients with glioblastoma
(GBM) remains dismal. An important obstacle against
treatment efficacy may be a high degree of intra- and
inter-tumoral heterogeneity within GBMs, which may be
caused by the presence of self-renewing GBM stem cells
(GSCs). Recent advances in multi-omics technology
introduce new possibilities for applying personalized
strategies to GBM therapy. As drug discovery is
accelerating with the transition from non-selective,
cytotoxic therapy to a precision, targeted approach, the
appropriate in vivo platform for GBM is critical for
validating drug targets and prioritizing candidates for
clinical studies, for co-development of companion
diagnostics and, ultimately, for drug approval. Here we
will describe GBM orthotopic patient-derived xenografts
(PDXs) as more useful, clinically relevant resources for
individually tailored strategies for GBM.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. CC BY 4.0